Clinical Trials Browser

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Pyloric Stenosis, Hypertrophic, Dendritic Cell Sarcoma, Interdigitating

NCT07249905 2026-03-03

Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma

Phase 1/2 Recruiting

180 enrolled

LymphoidSarcoma

Lymphoma, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone, Dendritic Cell Sarcoma, Interdigitating

NCT06014762 2026-02-27

P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies

Phase 1 Recruiting

120 enrolled

LymphoidSarcoma

Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating

NCT07121946 2026-02-10

This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma

Phase 1 Recruiting

42 enrolled

LymphoidSarcoma

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Dendritic Cell Sarcoma, Interdigitating

NCT05563844 2026-02-04

Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)

Phase 2 Active not recruiting

74 enrolled

Sarcoma

Dendritic Cell Sarcoma, Interdigitating

NCT03740529 2026-01-27

A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL

Phase 1/2 Completed

803 enrolled 4 FDA

LymphoidOther hematologic neoplasmSarcoma

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Dendritic Cell Sarcoma, Interdigitating

NCT07288879 2026-01-08

DALY II Japan

Phase 2 Recruiting

31 enrolled

Sarcoma

Dendritic Cell Sarcoma, Interdigitating

NCT06985576 2025-12-18

Long-term Study to Evaluate Safety and Persistence of GF-CART01

Not yet recruiting

18 enrolled

LymphoidSarcoma

Lymphoma, Follicular, Dendritic Cell Sarcoma, Interdigitating

NCT05526313 2025-10-01

Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory B Cell-related Tumor-predominant

Phase 1 Completed

29 enrolled

Sarcoma

Dendritic Cell Sarcoma, Interdigitating

NCT03162536 2025-09-08

ARQ 531-101

Phase 1/2 Active not recruiting

190 enrolled

LymphoidOther hematologic neoplasmPlasma cellSarcoma

Blood Protein Disorders, Cardiovascular Diseases, Hemorrhagic Disorders, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Leukemia, Lymphoid, Lymphatic Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Waldenstrom Macroglobulinemia, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Recurrence, Vascular Diseases, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Hematologic Neoplasms, Hemostatic Disorders, Lymphoma, Mantle-Cell, Neoplasms, Plasma Cell, Dendritic Cell Sarcoma, Interdigitating

NCT06830031 2025-06-13

C402

Phase 1 Recruiting

18 enrolled

LymphoidSarcoma

Lymphoma, B-Cell, Pyloric Stenosis, Hypertrophic, Dendritic Cell Sarcoma, Interdigitating

NCT05377307 2025-05-13

Long-term Follow-up Study of Lentiviral-based Gene-edited Immune Cell Therapy

Recruiting

49 enrolled

LymphoidSarcoma

Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating

Clinical Trials

SynKIR-310 for Relapsed/Refractory B-NHL

Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma

P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies

This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma

Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)

A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL

DALY II Japan

Long-term Study to Evaluate Safety and Persistence of GF-CART01

Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory B Cell-related Tumor-predominant

ARQ 531-101

C402

Long-term Follow-up Study of Lentiviral-based Gene-edited Immune Cell Therapy